Neo-Adjuvant Trials
| ClinicalTrials.gov Identifier: |
NCT04351555 |
This study is currently recruiting participants.
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
Alberta
Cross Cancer Institute, Edmonton
Contact: Quincy Chu 780 432-8248
Ontario
Kingston Health Sciences Centre, Kingston
Contact: Andrew Robinson 613 549-6666 ext 8104
Ottawa Hospital Research Institute, Ottawa
Contact: Sara Moore 613 737-7700
University Health Network, Toronto
Contact: Penelope A. Bradbury 416 946-4501 ext 3544
Quebec
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
Contact: Normand Blais 514 890-8444
The Research Institute of the McGill University, Montreal
Contact: Scott Owen 514 398-8307
Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval
Contact: Catherine Labbe 418 656-8711 ext 5504
| ClinicalTrials.gov Identifier: |
NCT04351555 |
This study is currently recruiting participants.
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer.
Ontario
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT03425643 |
This study is active but not currently recruiting.
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by blinded central pathologist or by imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) assessed by blinded independent central review (BICR); and 2) overall survival (OS).
Ontario
Princess Margaret Cancer Centre (Site 0109), Toronto
Contact: Study Coordinator 416-946-4501 x 3809
Quebec
CIUSSS du Saguenay-Lac-St-Jean (Site 0101), Chicoutimi
Contact: Study Coordinator 418-541-1234 x 2840
CIUSSS Ouest de l'ile-St-Mary's Hospital (Site 0104), Montreal
Contact: Study Coordinator 514-345-3511
| ClinicalTrials.gov Identifier: |
NCT02259621 |
This study is active but not currently recruiting.
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor immune milieu and circulating immune cells and soluble factors in these patients. Data obtained in this study will provide valuable information for planning further prospective clinical trials of anti-PD-1 and other immunotherapies in NSCLC, both in the peri-operative and advanced disease setting.
Quebec
Jonathan Spicer
Montreal
| ClinicalTrials.gov Identifier: |
NCT02998528 |
This study is active but not currently recruiting.
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.
Quebec
CISSS de l'Outaouais (Site 0095), Gatineau
McGill University Health Center (Site 0017), Montreal
St. Jerome
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du- Quebec (Site 0052), Trois-Rivieres,
Saskatchewan
Saskatoon Cancer Centre (Site 0016), Saskatoon
| ClinicalTrials.gov Identifier: |
NCT 03800134 |
This study is active but not currently recruiting.
This is a Phase III, randomized, double-blind placebo-controlled, multi-centre international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathalogical response.
Alberta
Edmonton
Ontario
Kitchener
London
Quebec
Levis
Montreal
Saskatchewan
Saskatoon
| ClinicalTrials.gov Identifier: |
NCT04025879 |
This study is active but not currently recruiting.
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Ontario
Windsor
Oshawa
Quebec
Greenfield Park
Montreal